Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.

Department of Cell Biology, Cleveland Clinic, Cleveland, Ohio 44195, USA.
Nature (Impact Factor: 42.35). 04/2011; 472(7341):57-63. DOI: 10.1038/nature09922
Source: PubMed

ABSTRACT Metabolomics studies hold promise for the discovery of pathways linked to disease processes. Cardiovascular disease (CVD) represents the leading cause of death and morbidity worldwide. Here we used a metabolomics approach to generate unbiased small-molecule metabolic profiles in plasma that predict risk for CVD. Three metabolites of the dietary lipid phosphatidylcholine--choline, trimethylamine N-oxide (TMAO) and betaine--were identified and then shown to predict risk for CVD in an independent large clinical cohort. Dietary supplementation of mice with choline, TMAO or betaine promoted upregulation of multiple macrophage scavenger receptors linked to atherosclerosis, and supplementation with choline or TMAO promoted atherosclerosis. Studies using germ-free mice confirmed a critical role for dietary choline and gut flora in TMAO production, augmented macrophage cholesterol accumulation and foam cell formation. Suppression of intestinal microflora in atherosclerosis-prone mice inhibited dietary-choline-enhanced atherosclerosis. Genetic variations controlling expression of flavin monooxygenases, an enzymatic source of TMAO, segregated with atherosclerosis in hyperlipidaemic mice. Discovery of a relationship between gut-flora-dependent metabolism of dietary phosphatidylcholine and CVD pathogenesis provides opportunities for the development of new diagnostic tests and therapeutic approaches for atherosclerotic heart disease.

Download full-text


Available from: Joseph A. DiDonato, Jun 25, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Atherosclerosis and associated cardiovascular disease (CVD) remain the largest causes of mortality in developed countries (Go et al., 2013). Despite widespread use of statins, CVD-associated mortality and morbidity have been reduced by only ∼30% (Go et al., 2013), demonstrating a clear need for better therapeutic strategies. Elevation of high-density lipoprotein (HDL) function is thought to be an attractive therapeutic strategy (Rader and Tall, 2012). However, recent clinical trials (Boden et al., 2011 and Schwartz et al., 2012) and Mendelian randomization studies (Voight et al., 2012) have failed to show clinical benefits of HDL cholesterol elevation, calling into question the role of HDL cholesterol as a surrogate marker of protection from atherosclerosis (Rader and Tall, 2012). Both proponents and critics alike of the “HDL hypothesis” agree on one thing: further studies are needed to understand the mechanism regulating the fundamental process of HDL-driven reverse cholesterol transport (RCT). The prevailing model for RCT is that cholesterol from the artery wall is delivered to the liver via HDL, from where it is then secreted into bile before leaving the body through the feces (Dietschy and Turley, 2002, Rader et al., 2009 and Rosenson et al., 2012). However, we and others have recently demonstrated that RCT can also proceed through a nonbiliary pathway known as transintestinal cholesterol excretion (TICE), which persists in both the surgical or genetic absence of biliary cholesterol secretion (Temel et al., 2010, Temel and Brown, 2012, Brown et al., 2008, Le May et al., 2013, van der Velde et al., 2007 and van der Veen et al., 2009). Under normal physiologic conditions the hepatobiliary route predominates and TICE is a minor pathway, only contributing ∼30% of the total cholesterol lost through the feces in mice (Temel and Brown, 2012). However, pharmacologic activation of liver X receptor (LXR) can preferentially stimulate the nonbiliary pathway to where TICE contributes greater than 60% of the total cholesterol lost through the feces (van der Veen et al., 2009). Although mechanisms regulating the classic hepatobiliary pathway of RCT have been well defined (Yu et al., 2002, Graf et al., 2003, Groen et al., 2008, Wiersma et al., 2009 and Temel et al., 2007), almost no mechanistic information exists for the nonbiliary TICE pathway (Temel and Brown, 2012 and Brufau et al., 2011).
    Cell Reports 01/2015; 66(3). DOI:10.1016/j.celrep.2014.12.036 · 7.21 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Increased understanding of the interactions between the gut microbiota, diet and environmental effects may allow us to design efficient treatment strategies for addressing global health problems. Existence of symbiotic microorganisms in the human gut provides different functions for the host such as conversion of nutrients, training of the immune system, and resistance to pathogens. The gut microbiome also plays an influential role in maintaining human health, and it is a potential target for prevention and treatment of common disorders including obesity, type 2 diabetes, and atherosclerosis. Due to the extreme complexity of such disorders, it is necessary to develop mathematical models for deciphering the role of its individual elements as well as the entire system and such models may assist in better understanding of the interactions between the bacteria in the human gut and the host by use of genome-scale metabolic models (GEMs). Recently, GEMs have been employed to explore the interactions between predominant bacteria in the gut ecosystems. Additionally, these models enabled analysis of the contribution of each species to the overall metabolism of the microbiota through the integration of omics data. The outcome of these studies can be used for proposing optimal conditions for desired microbiome phenotypes. Here, we review the recent progress and challenges for elucidating the interactions between the human gut microbiota and host through metabolic modeling. We discuss how these models may provide scaffolds for analyzing high-throughput data, developing probiotics and prebiotics, evaluating the effects of probiotics and prebiotics and eventually designing clinical interventions.
    Frontiers in Genetics 04/2014; 5:86. DOI:10.3389/fgene.2014.00086
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Soy foods Coronary heart disease Men Prospective cohort study Interleukin-8 Plasminogen activator inhibitor-1 Soy food intake has been associated with a reduced risk of coronary heart disease (CHD) in women, but its association with CHD in men is unclear [1–3]. Several studies have found sex differences in the associa-tions of soy intake with metabolic syndrome, endothelial function, and other cardiovascular risk factors [4,5]. In the Shanghai Men's Health Study [6], we investigated the association between soy food intake and incident CHD among 55,474 Chinese men (40–74 years) who were free of CHD, stroke, and cancer at baseline (2002–2006). We also examined the associations of soy intake with multiple CHD biomarkers in a subsample of 3885 men who provided fasting blood samples and had no history of major chronic diseases at recruitment.
    International Journal of Cardiology 03/2014; 172(2). DOI:10.1016/j.ijcard.2013.12.200 · 6.18 Impact Factor